KAPSPARGO SPRINKLE

Peak

metoprolol succinate

NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jan 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6

Mechanism of Action

1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic…

Indications (7)

hypertensionto lower blood pressurethe long-term treatment of angina pectoristo reduce angina attacksto improve exercise tolerancecardiovascular mortalityheart-failure hospitalization in patients with heart failure

Clinical Trials (5)

NCT05767346Phase 3Completed

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

Started Jun 2023
175 enrolled
Obstructive Hypertrophic Cardiomyopathy (oHCM)
NCT01508325Phase 4Completed

Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients

Started Dec 2011
186 enrolled
Hypertension
NCT00861016Phase 4Completed

Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension

Started Oct 2005
310 enrolled
Hypertension
NCT00077948Phase 3Terminated

Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure

Started Jul 2003
175 enrolled
Heart Failure, Congestive
NCT00642096Phase 3Completed

Factorial Study of Metoprolol Succinate TOPROL-XL (324A)

Started Jun 2003
1,900 enrolled
High Blood Pressure (Hypertension).

Loss of Exclusivity

LOE Date
Jul 9, 2035
113 months away
Patent Expiry
Jul 9, 2035

Patent Records (2)

Patent #ExpiryTypeUse Code
9504655
Jul 9, 2035
Product
—
9700530
Jul 9, 2035
Product
—
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers